Oral Transmucosal Drugs Market - 2022
The Oral Transmucosal Drugs Market was valued at USD 15,005.2 million in 2022 and is anticipated to reach by , at a CAGR of 0.064 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Oral Transmucosal Drugs Market.
This report delivers a comprehensive overview of the Oral Transmucosal Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Transmucosal Drugs Market. The Oral Transmucosal Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
Oral Transmucosal Drugs Market Scope:
By Product Type
This report delivers a comprehensive overview of the Oral Transmucosal Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Transmucosal Drugs Market. The Oral Transmucosal Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Oral Transmucosal Drugs Market.
This report delivers a comprehensive overview of the Oral Transmucosal Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Transmucosal Drugs Market. The Oral Transmucosal Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
Oral Transmucosal Drugs Market Scope:
By Product Type
- Tablets
- Films
- Liquids & Spray
- Others
- Opioid Dependence
- Neurological Disorders
- Erectile Dysfunction
- Nausea and Vomiting
- Others
- Sublingual Mucosa
- Buccal Mucosa
- Others
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Pfizer Inc.
- ZIM Laboratories Limited
- Aquestive Therapeutics, Inc
- IntelGenx Corp
- Indivior PLC
- C.L.Pharm Co., Ltd
- Seoul Pharmaceuticals
- Shilpa Therapeutics
- Sunovion Pharmaceuticals, Inc
- CURE Pharmaceutical
This report delivers a comprehensive overview of the Oral Transmucosal Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Transmucosal Drugs Market. The Oral Transmucosal Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
4.1.1.2. The increase in medication and pharmacological therapy usage
4.1.2. Restraints
4.1.2.1. Regulatory challenges for transmucosal drug
4.1.3. Opportunity
4.1.3.1. Increasing number of research and developments activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE CONFLICT ANALYSIS
8. GLOBAL RECESSION ANALYSIS
9. ARTIFICIAL INTELLIGENCE IMPACT ANALYSIS
10. BY PRODUCT TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.1.2. Market Attractiveness Index, By Product Type
10.2. Tablets
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Films
10.4. Liquids & Spray
10.5. Others
11. BY INDICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Opioid Dependence *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Neurological Disorders
11.4. Erectile Dysfunction
11.5. Nausea and Vomiting
11.6. Others
12. BY ROUTE OF ADMINISTRATION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Sublingual Mucosa *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Buccal Mucosa
12.4. Others
13. BY DISTRIBUTION CHANNEL
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.1.2. Market Attractiveness Index, By Distribution Channel
13.2. Retail Pharmacies*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Hospital Pharmacies
13.4. Online Pharmacies
14. BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. COMPANY PROFILES
16.1. Pfizer Inc.*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. ZIM Laboratories Limited
16.3. Aquestive Therapeutics, Inc
16.4. IntelGenx Corp
16.5. Indivior PLC
16.6. C.L.Pharm Co., Ltd
16.7. Seoul Pharmaceuticals
16.8. Shilpa Therapeutics
16.9. Sunovion Pharmaceuticals, Inc
16.10. CURE Pharmaceutical
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
4.1.1.2. The increase in medication and pharmacological therapy usage
4.1.2. Restraints
4.1.2.1. Regulatory challenges for transmucosal drug
4.1.3. Opportunity
4.1.3.1. Increasing number of research and developments activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE CONFLICT ANALYSIS
8. GLOBAL RECESSION ANALYSIS
9. ARTIFICIAL INTELLIGENCE IMPACT ANALYSIS
10. BY PRODUCT TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.1.2. Market Attractiveness Index, By Product Type
10.2. Tablets
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Films
10.4. Liquids & Spray
10.5. Others
11. BY INDICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Opioid Dependence *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Neurological Disorders
11.4. Erectile Dysfunction
11.5. Nausea and Vomiting
11.6. Others
12. BY ROUTE OF ADMINISTRATION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Sublingual Mucosa *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Buccal Mucosa
12.4. Others
13. BY DISTRIBUTION CHANNEL
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.1.2. Market Attractiveness Index, By Distribution Channel
13.2. Retail Pharmacies*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Hospital Pharmacies
13.4. Online Pharmacies
14. BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. COMPANY PROFILES
16.1. Pfizer Inc.*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. ZIM Laboratories Limited
16.3. Aquestive Therapeutics, Inc
16.4. IntelGenx Corp
16.5. Indivior PLC
16.6. C.L.Pharm Co., Ltd
16.7. Seoul Pharmaceuticals
16.8. Shilpa Therapeutics
16.9. Sunovion Pharmaceuticals, Inc
16.10. CURE Pharmaceutical
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
